Swiss Phase 2 biotech developing next-gen antibody drug conjugates for difficult cancers.
Industry: Health Care
First Day Return: +56.1%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 04/24/2020 |
Offer Price | $19.00 |
Price Range $16.00 - $18.00 | |
Offer Shares (mm) | 12.2 |
Deal Size ($mm) | $233 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 05/14/2020 |
Offer Price | IPO Intelligence Only |
Price Range | IPO Intelligence Only |
Offer Shares (mm) | IPO Intelligence Only |
Deal Size ($mm) | $233 |
Lock-Up Date | IPO Intelligence Only |
Street Research | IPO Intelligence Only |
Underwriters |
---|
IPO Intelligence Only |
Company Data | |
---|---|
Headquarters | Épalinges, Switzerland |
Founded | 2011 |
Employees at IPO | 138 |
Website www.adctherapeutics.com |